40 results on '"Egan Michael"'
Search Results
2. Pooled Modeling of Disease Progression in Two BACE1 Inhibitor Verubecestat Trials in Prodromal to Moderate Alzheimer’s Disease
3. Social network analysis of white‐tailed deer scraping behavior: Implications for disease transmission
4. Seasonal variations in nutritive and botanical composition properties of multispecies grazing swards over an entire dairy grazing season
5. The effect of autumn closing date on over winter tissue turnover in perennial ryegrass (Lolium perenne L.) swards
6. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
7. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS
8. FTS3-01-05: FURTHER ANALYSES OF COGNITIVE OUTCOMES IN THE APECS PHASE-3 TRIAL OF VERUBECESTAT IN PRODROMAL AD
9. P3-040: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE-RESPONSE RESULTS FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE
10. P1‐042: NEUROFIBRILLARY TANGLE IMAGING WITH [ 18 F]MK‐6240 IN APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE PATIENTS
11. O3-10-02: VERUBECESTAT-INDUCED BRAIN VOLUME LOSS OCCURS RAPIDLY AND ONLY IN AMYLOID-ENRICHED BRAIN REGIONS IN EPOCH, A PHASE 3 TRIAL IN MILD-TO-MODERATE ALZHEIMER'S DISEASE PATIENTS
12. High‐flow apnoeic oxygenation delivered by LMA or tracheal tube for tracheal resection and reconstruction surgery
13. Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease
14. ACUTE ADMINISTRATION OF A BACE INHIBITOR IN HEALTHY HUMANS RESULTS IN A SIGNIFICANT REDUCTION OF Aβ OLIGOMERS IN CEREBROSPINAL FLUID
15. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
16. P2-014: Relationship Between Volumetric MRI Parameters, APOE4 and MMSE Status at Baseline in The Verubecestat (MK-8931) Mild to Moderate Alzheimer’s Disease Phase 2/3 Trial
17. P4-380: BACE Inhibitor Verubecestat (MK-8931): Baseline Characteristics for Participants Enrolled in the Phase II/III Epoch Alzheimer’S Disease Trial
18. P4-040: Does Regional Amyloid Burden Impact Domain-Specific Cognitive Impairment?
19. P2-005: Evidence from Model-Based Assessments of Compounds Tested in Completed Clinical Trials Indicates That The Amyloid Hypothesis Has Not Been Adequately Tested
20. P2-318: Assessing Geographic Variability in Cognitive and Functional Baseline Scores in a Large Multinational Trial of Mild-to-Moderate Alzheimer's Disease
21. P1-107: Is the Peripheral Sink Hypothesis Physiologically Feasible? Evidence from Model-Based Assessment of the Amyloid Pathway
22. P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease
23. F5-02-04: Cerebrospinal fluid amyloid oligomers measured in a subset of the aibl and optima age-matched healthy control and Alzheimer's cohorts
24. Response to Voepel‐Lewis and Malviya's comment ‘pain score guided morphine titration is risky and inappropriate’
25. MORPHIT: an observational study on morphine titration in the postanesthetic care unit in children
26. O1–06–05: The novel BACE inhibitor MK‐8931 dramatically lowers CSF beta‐amyloid in patients with mild‐to‐moderate Alzheimer's disease
27. Randomized controlled study of the T‐type calcium channel antagonist MK‐8998 for the treatment of acute psychosis in patients with schizophrenia
28. P1‐334: Development and application of a mathematical model of modulation of cerebrospinal fluid Aβ40 after treatment with gamma‐ and beta‐secretase inhibitors
29. P1-045: Methodologic issues in planning an efficacy trial in prodromal Alzheimer's disease for therapies targeting Aβ
30. O2-05-06: Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of Alzheimer's disease
31. Minimal invasive surgery for hip replacement: a new technique using the NILNAV hip system
32. Neonatal ventral hippocampal damage modifies serum corticosterone and dopamine release responses to acute footshock in adult Sprague‐Dawley rats
33. Changes in the pattern of brain-derived neurotrophic factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment
34. Neonatal excitotoxic ventral hippocampal damage alters dopamine response to mild repeated stress and to chronic haloperidol
35. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic‐induced dyskinesias
36. 3‐Methoxytyramine Is the Major Metabolite of Released Dopamine in the Rat Frontal Cortex: Reassessment of the Effects of Antipsychotics on the Dynamics of Dopamine Release and Metabolism in the Frontal Cortex, Nucleus Accumbens, and Striatum by a Simple Two Pool Model
37. Absence of 6‐Hydroxydopamine in the Rat Brain After Treatment with Stimulants and Other Dopaminergic Agents: A Mass Fragmentographic Study
38. The association of amyloid deposits and osteoarthritis
39. Relative frequency of gout and pseudogout
40. Ecological Shifts in Sympatry: Kalahari Fossorial Lizards (Typhlosaurus)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.